In the future, therapeutics aimed at interfering with these pathological TIM-1+Breg cells and the HMGB1-TLR2/4-MAPK immunosuppressive pathway may be developed to provide novel strategies for HCC treatment. Here, HMGB1 is linked to hepatocellular carcinoma.